MARK ALAN GOLDBERG, MD
Osteopathic Medicine at Francis St, Boston, MA

5304189, Apr 19, 1994

Apr 9, 1992

7/865850

Mark Goldberg - Boston MA
Alexander Poloyko - Morton Grove IL
Edward M. Goldberg - Glencoe IL
Lev Melinyshyn - Buffalo Grove IL

Lafeber Company - Odell IL

A61B 1732

606159

An improved valve cutter for in-situ incision of valve leaflets which safely, efficiently, and consistently renders venous valves incompetent while minimizing frictional forces on the endothelium of the vessel and preventing inadvertent contact between cutting surfaces and the intima of the vein wall. The valve cutter includes a plurality of proximally directed prongs presenting sharp edges, where the prongs are separated by slots similarly presenting sharp edges to pierce the valve leaflets so that the cutting head is provided with a continuous cutting surface in multiple planes running along the entire forward edge of the cutting head.

5339801, Aug 23, 1994

Mar 12, 1992

7/850652

Alexander Poloyko - Morton Grove IL
Mark C. Goldberg - Boston MA
Edward M. Goldberg - Glencoe IL
Lev A. Melinyshyn - Buffalo Grove IL
David E. Schucart - Homewood IL

UreSil Corporation - Skokie IL

A61B 1702

128 20

A surgical retractor having a plurality of widenable and narrowable blades of substantial width, having tissue-contacting surfaces that are not significantly narrower, in a collapsed position, than a guide tube for guiding the retractor blades through a surgical access port to a surgical site during a minimally invasive surgical procedure. Each retractor blade includes a relatively large, preferably planar, tissue-contacting surface for displacing or repositioning internal body tissue, such as an internal organ, for temporary displacement away from the surgical site. After insertion through a surgical access port one or more of the retractor blades can be widened laterally to substantially space distal ends of the retractor blades apart for maximum contact against and over a substantial area of the tissue to be displaced during the surgical procedure. After completion of the operative procedure, the retractor blades can be narrowed by nesting the blades together and the retractor can be easily and safely withdrawn from the access port.

5369014, Nov 29, 1994

Aug 17, 1992

7/930361

Carlo Brugnara - Newton Highlands MA
Margot S. Kruskall - Dover MA
Mark A. Goldberg - Boston MA
Linda A. Chambers - Worthington OH

Beth Israel Hospital Assoc. - Boston MA

C12Q 102, C12Q 100

435 29

The present invention is an in-vitro blood assay method for determining the past and/or present use of exogenous erythropoietin by a living subject. The blood assay method detects, identifies, and determines the consequences of using an exogenous erythropoietin to generate an increase in red blood cell production in the living subject and provides a methodology by which to detect and determine both surreptitious as well as authorized therapeutic uses and applications of erythropoietin.

5480975, Jan 2, 1996

Feb 8, 1994

8/193569

Mark A. Goldberg - Boston MA
Andrew P. Levy - Brookline MA

Brigham and Women's Hospital - Boston MA

A61K 3324, A61K 3330, A61K 3332, A61K 3334

530399

Transition metal ions enhance the ability of the body to increase vascularization, particularly for revascularizing damaged tissues, apparently because they enhance expression of the vegF gene, so as to increase VEGF levels. According, hypoxic tissue damage can be treated or prophylactically reduced by administering a composition comprising a transition metal ion capable of stimulating vascularization. Treatment can be accomplished using compositions of matter which include a transition metal ion in a sterile, biologically compatible carrier, packaged as a unit dosage effective to increase vascularization in hypoxic tissue. For systemic administration, the transition metal ion is formulated at a concentration that is non-toxic and ineffective to increase vascularization in non-hypoxic tissue. For local administration, the transition metal ions are formulated in a slow-releasing carrier to release the transition metal ions continually over a prolonged period in an amount effective to increase vascularization locally. For example, for topical application, the composition may be a salve, a gel, or a patch.

5188828, Feb 23, 1993

Nov 8, 1990

7/610221

Mark A. Goldberg - Boston MA
William C. Faquin - Boston MA

Brigham and Women's Hospital - Boston MA

A61K 4505, C07K 1300

424 852

The invention is directed to the administration of Interleukin 6 for the purpose of enhancing endogenous erythropoietin levels in vitro and in vivo. The invention further encompasses methods of treatment of disorders characterized by, or including, erythropoietin deficiency. Such disorders include the anemias of chronic inflammation, renal failure, AIDS, and malignancy.